Strategic expansion of Diamyd Medical's European Phase II trial in Type 1 diabetes
This is a resubmission of the earlier press release on August 21, 2018, in which it was incorrectly referred to the Market Abuse Regulation. The Swedish Medical Products Agency has approved an expansion of DIAGNODE-2, the Phase II trial where the diabetes vaccine Diamyd® is administered directly into the lymph node, to comprise a total of approximately 106 patients. The expansion, which is awaiting approval in Spain and the Czech Republic, is being made to increase the trial’s statistical power and weight in the development of the antigen-specific intralymphatic immunotherapy Diamyd® for
